Minutes of Implanet’s Annual General Meeting Held on May 3, 2023
04 Mai 2023 - 6:00PM
Business Wire
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME equity savings plans), a medical technology company
specializing in vertebral implants for orthopedic surgery and the
distribution of technological medical equipment, informs its
shareholders that its Annual General Meeting was held on Wednesday
May 3, 2023, at 2:00 pm CEST at the Company's registered office, in
Martillac.
The number of shares held by the shareholders present or
represented was 17,113,846, representing a quorum of 43.70%.
All the resolutions of this Annual General Meeting were adopted,
except for the fourteenth resolution, in accordance with the
recommendations of the Board of Directors. Among the resolutions
adopted was the approval of the appointment of Mr. David FAN,
co-founder and Deputy CEO of Sanyou Medical, to the Board of
Directors for a period of three years. The shareholders also
renewed the appointment of Mrs. Paula Ness Speers as a Director for
a further three years.
The minutes of the General Meeting will be available within the
legal deadlines on the Company's website:
www.implanet-invest.com/general-meeting
Upcoming financial events:
- H1 2023 revenue, July 11, 2023,
after market - H1 2023 results, September 19, 2023, after
market
About IMPLANET Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery and distributing medical technology equipment.
Its activity revolves around a comprehensive innovative solution
for improving the treatment of spinal pathologies (JAZZ®)
complemented by the product range offered by Orthopaedic &
Spine Development (OSD), acquired in May 2021 (thoraco-lumbar
screws, cages and cervical plates). Implanet’s tried-and-tested
orthopedic platform is based on the traceability of its products.
Protected by four families of international patents, JAZZ® has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States, the CE mark in Europe
and ANVISA approval in Brazil. In 2022, IMPLANET entered into a
commercial, technological and financial partnership with SANYOU
MEDICAL, China's second largest medical device manufacturer.
IMPLANET employs 43 staff and recorded a consolidated revenue of
€8.0 million in 2022. Based near Bordeaux in France, IMPLANET
opened a US subsidiary in Boston in 2013. IMPLANET is listed on the
Euronext Growth market in Paris. For further information, please
visit www.Implanet.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504005834/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Implanet (EU:ALIMP)
Historical Stock Chart
Von Apr 2023 bis Apr 2024